Radiofrequency Ablation Devices Market to Experience Growth at a Tremendous CAGR of 9.34% Reaching USD 5.69 Billion by 2026, Asserts DelveInsight

- The market for Radiofrequency Ablation Devices is witnessing huge growth due to the growing prevalence of chronic diseases such as cardiovascular diseases, cancers, rising geriatric population, and technological advancements in product development and design improvement.

LAS VEGAS, Feb. 16, 2022 /PRNewswire/ -- DelveInsight's Radiofrequency Ablation Devices Market Insights and Forecast report provides the current and forecast Radiofrequency Ablation Devices Market, upcoming innovation in the devices, individual market shares, challenges, drivers, and barriers, market trends, and key competitors in the Radiofrequency Ablation Devices Market. 

Some of the salient features from the Radiofrequency Ablation Devices Market report: 

• As per DelveInsight analysis, in terms of revenue share, North America is predicted to register the fastest growth in the Radiofrequency Ablation Devices market.
• Key Radiofrequency Ablation Devices companies proactively working to develop novel devices include names such as BIOTRONIK Schweiz AG, Medtronic, Abbott, Olympus., Stryker, Boston Scientific Corporation, AngioDynamics., CONMED Corporation, Lepu Medical Technology (Beijing) Co.,Ltd, Arthrex, Inc., STARmed Co., Ltd., HOLOGIC, INC, Baylis Medical Company, Inc, Medical Devices Business Services, Inc.(Johnson & Johnson), Smith & Nephew, Sutter Medizintechnik GmbH, Bramsys, RF Medical Co., Ltd, OSYPKA AG, Avanos Medical, Inc., and others.
• DelveInsight analyzes that Global Radiofrequency Ablation Devices Market was valued at USD 3.35 billion in 2020, and is expected to grow at a substantial CAGR of 9.34% during the forecast period from 2021 to 2026. The Radiofrequency Ablation Devices market size is anticipated to reach USD 5.69 billion by 2026.
• In October 2021, Venclose Inc received the 510k FDA clearance for their Maven endovenous radiofrequency ablation (RFA) catheter for minimally invasive treatment of incompetent perforator veins (IPVs).
• On January 28, 2021, Medtronic announced the FDA approved its temperature-controlled, irrigated radiofrequency ablation system with diamonds - DiamondTemp Ablation Catheters - P200028, for the treatment of paroxysmal atrial fibrillation that is unresponsive to drug therapy.
• In August 2020, Biosense Webster, a Johnson & Johnson Medical Devices Companies subsidiary, received European CE mark approval for their QDOT MICRO radiofrequency (RF) ablation catheter.
• In February 2020, Avanos Medical, Inc. received FDA approval for marketing of its new, 80-Watt COOLIEF Radiofrequency (RF) system for neurological lesion procedures.

To pick on the latest highlights related to Radiofrequency Ablation Devices, get the snapshot of the key highlights entailed in the Radiofrequency Ablation Devices Detailed Report

Radiofrequency Ablation Devices Overview 

Radiofrequency Ablation procedures are a type of medical devices that are considered appropriate for minimally invasive procedures of patients with cardiac diseases (such as atrial fibrillation (AF), atrial flutter, cardiac arrhythmias), cancer and pain management. They provide an option of treating diseases such as arrhythmia and various cancers with the use of thermal energy under controlled temperatures. Few of the Radiofrequency Ablation side effects include discomfort, swelling, and bruising at the site of the treatment, but this generally goes away after a few days

Radiofrequency Ablation Devices Market Insight 

Among all the regions, North America is expected to account for the significant market share in the Radiofrequency Ablation Devices market. This domination is attributed to various aspects such as lower back pain, neck pain, and arthritis among the rising population of elderly as well as high awareness among people regarding disease management and the new product launches in the region. Furthermore, a well-established patient care system along with knowledge regarding medical devices among patients and caregivers specifically for different types of radiofrequency ablation devices is further expected to propel the Radiofrequency Ablation Devices market growth. 

In addition to that, the presence of key players in the region and supportive reimbursement programs further provide immense growth opportunities for the Radiofrequency Ablation Devices market. For instance, in February 2020, Boston Scientific Corporation received the product approval from the Canadian medical device regulatory authority, Health Canada for their IntellaNav StablePoint Ablation Catheter which is indicated to be used in conjunction with a radio frequency (RF) generator for carrying out cardiac ablation.

Click here to understand more about the Radiofrequency Ablation Devices Market Landscape @ Radiofrequency Ablation Devices Assessment

Radiofrequency Ablation Devices Market Dynamics 

There is a rise in demand for Radiofrequency Ablation Devices observed in recent years due to many factors such as the growing prevalence of chronic diseases such as cardiovascular diseases, cancers, rising geriatric population, technological advancements in product development and design improvement as well as the entrance of key market players in the Radiofrequency Ablation Devices market. Moreover, Radiofrequency Ablation Devices are a popular method that is employed for atrial fibrillation treatment so the rise in atrial fibrillation cases globally, it will aid the Global Radiofrequency Ablation Devices market growth. Also, the rising prevalence of cancers of different etiologies, and comparatively lower Radiofrequency Ablation cost is expected to contribute to the growing demand for Radiofrequency Ablation Devices, eventually taking the radiofrequency ablation devices market forward during the forecast period. 

The Radiofrequency Ablation Devices market witnessed a period of temporary setback due to the imposing of the lockdown restrictions as necessary measures to contain the COVID-19 spread. One of the major steps during this was the suspension of numerous elective procedures and outpatient visits which reduced the demand for Radiofrequency Ablation Devices in the market as various Radiofrequency Ablation procedures were deemed non-essential during the initial lockdown period, thereby limiting the market growth for a short time.

Get a sneak peek at the Radiofrequency Ablation Devices market drivers & barriers @ Radiofrequency Ablation Devices Market Drivers Analysis

Scope of the Radiofrequency Ablation Devices Market Report

• Coverage: Global
• Study Period: 2021-2026
• Market Segmentation By Product Type - Radiofrequency Generators, Radiofrequency Catheters, Rf Electrodes, And Others)
• Market Segmentation By Application -Cardiology, Surgical Oncology, Pain Management, And Others
• Market Segmentation By End-User - Hospitals, Specialty Clinics, And Others
• Market Segmentation By Geography - North America, Europe, Asia-Pacific, and Rest of World
• Key Radiofrequency Ablation Devices Companies - BIOTRONIK Schweiz AG, Medtronic, Abbott, Olympus., Stryker, Boston Scientific Corporation, AngioDynamics., CONMED Corporation, Lepu Medical Technology (Beijing) Co.,Ltd, Arthrex, Inc., STARmed Co., Ltd., HOLOGIC, INC, Baylis Medical Company, Inc, Medical Devices Business Services, Inc.(Johnson & Johnson), Smith & Nephew, Sutter Medizintechnik GmbH, Bramsys, RF Medical Co., Ltd, OSYPKA AG, Avanos Medical, Inc., and others.
• Porter's Five Forces Analysis
• Product Profiles
• Case Studies 
• KOL's Views
• Analyst's View

Delveinsight Analysis: The Global Radiofrequency Ablation Devices market is expected to grow at a compound annual growth rate (CAGR) of 9.34% during the forecast period and will reach USD 5.69 billion by 2026.

Know more about which MedTech player is set to emerge as the trendsetter @ Key Radiofrequency Ablation Devices Companies

Table of Contents 

Learn more about the report offerings @ Radiofrequency Ablation Devices Regulatory And Patent Analysis

Related Reports

Non-muscle Invasive Bladder Cancer Market

DelveInsight's 'Non-muscle Invasive Bladder Cancer (NMIBC) Market Insights, Epidemiology and Market Forecast–2030' report deliver an in-depth understanding of the NMIBC, historical and forecasted epidemiology as well as the NMIBC market trends, market drivers, market barriers and key NMIBC companies involved such as FKD Therapies Oy, Ferring Pharmaceuticals, Merck, Viventia Bio, Sesen Bio, CG Oncology, ImmunityBio, Altor Biosciences, Theralase, and many others. 

Cardiac Valvulotome Market

"DelveInsight's 'Cardiac Valvulotome Market Insight, Competitive Landscape and Market Forecast, 2026' report delivers an in-depth understanding of Cardiac Valvulotome and the historical and forecasted Cardiac Valvulotome market trends, globally, which comprises of North America, Europe, APAC, and RoW, market drivers & barriers, unmet needs, and key Cardiac Valvulotome companies involved such as Braun Melsungen AG, LeMaitre Vascular, Inc., Andramed GmbH,BD., InvaMed, Koven Technology Canada Inc, and others.

Cardiac Resynchronization Therapy Market

"DelveInsight's 'Cardiac Resynchronization Therapy Market Insight, Competitive Landscape and Market Forecast, 2026' report delivers an in-depth understanding of Cardiac Resynchronization Therapy and the historical and forecasted Cardiac Resynchronization Therapy market trends, globally, which comprises of North America, Europe, APAC, and RoW, market drivers & barriers, unmet needs, and key Cardiac Resynchronization Therapy companies involved such as Boston Scientific Corporation, Medtronic, Medico S.p. A, Microport Scientific Corporation, Biotronik, EBR Systems, Abbott, and others.

Cardiac Restoration Systems Market 

"DelveInsight's 'Cardiac Restoration Systems Market Insight, Competitive Landscape and Market Forecast, 2026' report delivers an in-depth understanding of Cardiac Restoration Systems and the historical and forecasted Cardiac Restoration Systems market trends, globally, which comprises of North America, Europe, APAC, and RoW, market drivers & barriers, unmet needs, and key  Cardiac Restoration Systems companies involved such as Abbott, BioVentrix, CryoLife, Edwards Lifesciences Corporation,NeoChord, XELTIS, and others.

Cardiac Output Monitors Market 

"DelveInsight's 'Cardiac Output Monitors Market Insight, Competitive Landscape and Market Forecast, 2026' report delivers an in-depth understanding of Cardiac Output Monitors and the historical and forecasted market trends, globally, which comprises of North America, Europe, APAC, and RoW, market drivers & barriers, unmet needs, and key Cardiac Output Monitors companies involved such as Osypka Medical GmbH, CNSystems Medizintechnik GmbH., Uscom,Deltex Medical Limited, Edward Lifesciences Corporation, ICU Medical, Inc., LiDCO, Baxter., Getinge AB., GE Healthcare (GENERAL ELECTRIC COMPANY), Biotronik, and others.

Cardiac Monitoring Devices Market

Global Cardiac Monitoring Devices Market report delivers an in-depth understanding of Cardiac Monitoring Devices and the historical and forecasted market trends, market drivers & barriers, unmet needs, and key Cardiac Monitoring Devices companies involved such as Medtronic, Boston Scientific, Abbott Laboratories, GE Healthcare, BIOTRONIK, and Koninklijke Philips, Asahi Kasei Corporation, MicroPort Scientific Corporation, Hill-Rom Holdings, Nihon Kohden, SCHILLER AG, BioTelemetry, BPL Medical Technologies, ACS Diagnostics, and others.

Cardiac Biomarkers Testing Market

Global Cardiac Biomarkers Testing Market was valued at USD 3.25 billion in 2020, growing at a CAGR of 7.76% during the forecast period from 2021 to 2026 to reach USD 5.07 billion by 2026. The report delivers an in-depth understanding of Global Cardiac Biomarkers Testing and the historical and forecasted market trends, market drivers & barriers, unmet needs, and key  Global Cardiac Biomarkers Testing companies involved such as Beckman Coulter, Siemens Healthcare GmbH, Abbott, bioMérieux SA, F. Hoffmann-La Roche Ltd, Thermo Fischer Scientific Inc, Bio-Rad Laboratories Inc, Eurolyser Diagnostica GmbH, Diagnostic Automation / Cortez Diagnostics, Randox Laboratories Ltd, Tosoh Corporation, DIALAB GmbH, CardioGenics Holdings Inc, and others.

Cardiac Assist Devices Market 

Global Cardiac Assist Devices Market was valued at USD 2.55 billion in 2020, growing at a CAGR of 13.70% during the forecast period from 2021 to 2026, to reach USD 5.50 billion by 2026. The report delivers an in-depth understanding of Global Cardiac Assist Devices and the historical and forecasted market trends, market drivers & barriers, unmet needs, and key Global Cardiac Assist Devices companies involved such as Abbott Laboratories, Teleflex Incorporated, SynCardia Systems, LLC, St. Jude Medical Inc, CARMAT, CorWave SA, Medtronic PLC, Terumo Heart, NovaPump GmbH, Getinge AB Balton Ltd, Meril Life Sciences Pvt. Ltd, Thoratec Corporation, and others.

Interested to know more about the breakthrough happenings? Take a look at the posts below 

• Medical Devices Market Blooms as the Key MedTech Companies Continue to Bring-In Innovation
• With advancements in Innovative Technology, Cardiac Monitoring Devices Market is Booming Significantly
• Mapping the Increasing Burden of Heart Failure: What Does it Bring for Healthcare Market Companies?

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Connect With Us at LinkedIn | Facebook | Twitter

Contact Us

Shruti Thakur 
info@delveinsight.com 
+1(919)321-6187 
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg